dipyridamole has been researched along with Obesity in 4 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A retrospective comparison of wall motion and myocardial perfusion with RTCSE was assessed in 481 obese and 961 nonobese patients matched for age and gender without known coronary artery disease referred for either dobutamine (n = 1,056) or dipyridamole (n = 386) stress echocardiography at two separate institutions." | 3.83 | Effect of Pharmacologic Stress Test Results on Outcomes in Obese versus Nonobese Subjects Referred for Stress Perfusion Echocardiography. ( Gaibazzi, N; Lorenzoni, V; Porter, TR; Reverberi, C; Wu, J; Xie, F, 2016) |
| "We enrolled 129 patients with true RHTN regularly followed in our specialty hypertension clinic and evaluated then by resting and dipyridamole pharmacological stress myocardial perfusion scintigraphy." | 3.81 | Predictors of silent myocardial ischemia in resistant hypertensive patients. ( Barbaro, NR; Calhoun, DA; de Faria, AP; Fontana, V; Modolo, R; Moreno, H; Nascimento, BB; Paganelli, MO; Ramos, CD; Sabbatini, AR, 2015) |
| " Moreover, patients without any history of coronary heart disease and showing a normal resting ECG underwent a bicycle exercise test or a dipyridamole thallium scintigraphy to detect possible silent myocardial ischemia." | 3.69 | Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM. ( Brun, JM; Cohen, M; Gambert, P; Lagrost, L; Petit, JM; Vaillant, G; Vergès, BL, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Modolo, R | 1 |
| de Faria, AP | 1 |
| Paganelli, MO | 1 |
| Sabbatini, AR | 1 |
| Barbaro, NR | 1 |
| Nascimento, BB | 1 |
| Ramos, CD | 1 |
| Fontana, V | 1 |
| Calhoun, DA | 1 |
| Moreno, H | 1 |
| Gaibazzi, N | 1 |
| Lorenzoni, V | 1 |
| Reverberi, C | 1 |
| Wu, J | 1 |
| Xie, F | 1 |
| Porter, TR | 1 |
| Gimelli, A | 1 |
| Marzullo, P | 1 |
| L'Abbate, A | 1 |
| Rovai, D | 1 |
| Vergès, BL | 1 |
| Lagrost, L | 1 |
| Vaillant, G | 1 |
| Petit, JM | 1 |
| Cohen, M | 1 |
| Gambert, P | 1 |
| Brun, JM | 1 |
4 other studies available for dipyridamole and Obesity
| Article | Year |
|---|---|
Predictors of silent myocardial ischemia in resistant hypertensive patients.
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Asymptomatic Diseases; Blood Pressure; Blood Pres | 2015 |
Effect of Pharmacologic Stress Test Results on Outcomes in Obese versus Nonobese Subjects Referred for Stress Perfusion Echocardiography.
Topics: Age Distribution; Aged; Causality; Comorbidity; Coronary Artery Disease; Dipyridamole; Dobutamine; E | 2016 |
'False-positive' myocardial perfusion imaging: correlation with cardiovascular risk factors and effect on event-free survival.
Topics: Aged; Angina Pectoris; Coronary Circulation; Diabetes Mellitus; Dipyridamole; Electrocardiography; E | 2008 |
Macrovascular disease is associated with increased plasma apolipoprotein A-IV levels in NIDDM.
Topics: Apolipoproteins A; Biomarkers; Blood Glucose; Blood Pressure; Cerebrovascular Disorders; Cholesterol | 1997 |